These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16502833)

  • 1. [Your patients face the treatment of osteoporosis: How to improve the efficacy of management in clinical practice?].
    Thomas T; Reach G; Lespessailles E
    Rev Prat; 2006 Jan; Spec No():3-11. PubMed ID: 16502833
    [No Abstract]   [Full Text] [Related]  

  • 2. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
    MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When do bisphosphonates make the most sense?
    Winzenberg T; Jones G
    J Fam Pract; 2011 Jan; 60(1):18-28. PubMed ID: 21209974
    [No Abstract]   [Full Text] [Related]  

  • 5. [Patient compliance program aids therapy success].
    MMW Fortschr Med; 2009 Mar; 151(11):47. PubMed ID: 19469207
    [No Abstract]   [Full Text] [Related]  

  • 6. [What do we need to know--what can we do?].
    Krankenpfl J; 2005; 43(7-10):217. PubMed ID: 16515289
    [No Abstract]   [Full Text] [Related]  

  • 7. Who will benefit from antiresorptive treatment (bisphosphonates)?
    Papapoulos SE
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):965-73. PubMed ID: 16301190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroids: no drug prevention of fractures needed.
    Prescrire Int; 2009 Aug; 18(102):175. PubMed ID: 19746563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoporosis therapy. Bisphosphonates compared].
    MMW Fortschr Med; 2003 Mar; 145(13):60. PubMed ID: 15101545
    [No Abstract]   [Full Text] [Related]  

  • 11. [Excellent adjustment with greater action. To pay attention to improving compliance].
    MMW Fortschr Med; 2005 Apr; 147(14):45. PubMed ID: 15887686
    [No Abstract]   [Full Text] [Related]  

  • 12. [Risedronate (Actonel)--from randomized clinical trials to real life].
    Anić B
    Reumatizam; 2007; 54(2):85-6. PubMed ID: 18351152
    [No Abstract]   [Full Text] [Related]  

  • 13. [Men also need bone protection].
    MMW Fortschr Med; 2006 Nov; 148(46):48-9. PubMed ID: 17615790
    [No Abstract]   [Full Text] [Related]  

  • 14. One drug tackles two diseases.
    Br Dent J; 2005 Dec; 199(11):701. PubMed ID: 16341176
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevent, treat and maintain: a new goal for osteoporosis management in clinical practice.
    Gandolini G; Migliaccio S; Bevilacqua M; Lello S; Malavolta N
    Aging Clin Exp Res; 2004 Jun; 16 Suppl(3):37-41. PubMed ID: 15506700
    [No Abstract]   [Full Text] [Related]  

  • 16. [To treat effectively without delay. The data on fractures decisive].
    MMW Fortschr Med; 2003 May; 145(21):56-7. PubMed ID: 12845873
    [No Abstract]   [Full Text] [Related]  

  • 17. Bisphosphonate therapy for osteoporosis.
    Attie MF
    Hosp Pract (Off Ed); 1991 Mar; 26(3A):87-90. PubMed ID: 1900862
    [No Abstract]   [Full Text] [Related]  

  • 18. Persistence with bisphosphonate therapy in older people.
    Melo M; Qiu F; Sykora K; Juurlink D; Laupacis A; Mamdani M
    J Am Geriatr Soc; 2006 Jun; 54(6):1015-6. PubMed ID: 16776810
    [No Abstract]   [Full Text] [Related]  

  • 19. [Correlation between studies and general practice].
    MMW Fortschr Med; 2006 Nov; 148(46):49. PubMed ID: 17615791
    [No Abstract]   [Full Text] [Related]  

  • 20. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
    Bilbao J; Pugh A; Aspy CB
    J Okla State Med Assoc; 2010 Aug; 103(8):374-5. PubMed ID: 21049709
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.